Table 6 Demographic, clinical, immunological and histopathological characteristics and clinical outcomes of ESRD and non-ESRD groups

Age (years)

Median (range)

38 (24)

22–65

38 (32)

20–68

0.27

Gender (%)

 Male

 Female

24 (40%)

36 (60%)

19 (46.3%)

22 (53.7%)

0.52

BMI (Kg/m²)

25.8 (1.5)

26.56 (3.7)

23–31.64

22–29

0.22

HTN (%)

51 (85%)

18 (43.9%)

< 0.001

Edema (%)

40 (66.7%)

15 (36.6%)

0.003

Microscopic hematuria (%)

47 (78.3%)

31 (75.6%)

0.75

Macroscopic hematuria (%)

13 (21.7%)

10 (24.4%)

0.75

Oliguria (%)

47 (78.3%)

8 (19.5%)

< 0.001

Fever (%)

16 (26.7%)

6 (14.6%)

0.15

Skin rash (%)

24 (40%)

10 (24.4%)

0.1

Hemoptysis (%)

26 (43.3%)

4 (9.8%)

< 0.001

Arthritis (%)

30 (50%)

16 (39%)

0.27

Need for HD at presentation (%)

49 (81.7%)

6 (14.6%)

< 0.001

Serum creatinine at presentation (mg/dL)

5.4 (2.4)

2.7 (1.0)

1.2–8

1.2–5.8

< 0.001

GFR at presentation (ml/min/1.73²)

11 (5)

27 (6.5)

6–81

9–63

< 0.001

Hb (gm/dL)

8.0 (1.3)

9.5 (1.1)

6.6–9.6

8–10.5

< 0.001

Serum albumin (gm/dL)

2.0 (0.9)

2.7 (0.9)

1.6–3.1

1.8–3.1

0.002

Proteinuria (gm/day)

5 (2.1)

4.0 (1.3)

2.5–12

2–8

0.001

Low C3 (%)

30 (50%)

14 (34.1%)

0.11

Low C4 (%)

22 (36.7)

12 (29.3%)

0.44

+ve ANA (%)

22 (36.7)

12 (29.3%)

0.44

+ve AntidsDNA (%)

22 (36.7)

12 (29.3%)

0.44

+ve AntiGBM (%)

12 (20%)

4 (9.8%)

0.16

+ve P-ANCA(%)

7 (11.7%)

6 (14.6%)

0.66

+ve C-ANCA (%)

6 (10.%)

2 (4.9%)

0.35

Total number of glomeruli

20 (6)

17 (5.5)

12–26

12–30

0.004

Number of normal glomeruli

3 (2)

4 (2.5)

0–11

2–14

0.028

Number of sclerotic glomeruli

6 (3)

1.0 (2)

1–9

0–7

< 0.001

Number of crescentic glomeruli

11(3)

13.0 (4)

0.07

7–16

5–19

Number of fibrous crescents

3.0 (1)

1.0 (1)

1–7

0–3

< 0.001

Number of cellular crescents

8.0 (2.75)

11.0 (4.0)

4–12

5–16

< 0.001

Glomerular lesions (%)

 Endocapillary proliferation (%)

 Mesangial proliferation (%)

 Glomerular thrombosis (%)

 Neutrophilic infiltration (%)

32 (53.3%)

41 (68.3%)

9 (15%)

46 (76.7%)

18 (43.9%)

10 (24.4%)

0 (0%)

21 (51.2%)

0.35

< 0.001

0.009

0.008

Moderate to severe IFTA (%)

48 (80%)

6 (14.6%)

< 0.001

TLO formation (%)

38 (63.3%)

10 (24.4%)

< 0.001

Vascular lesions

 Fibrinoid necrosis

 Degree of severe arteriosclerosis (%)

25 (41.7%)

46 (76.7%)

6 (14.6%)

2 (4.9%)

0.004

< 0.001

Infections (%)

38 (63.3%)

8 (19.5%)

< 0.001

Heart failure (%)

34 (56.7%)

6 (14.6%)

< 0.001

Respiratory failure (%)

27 (45%)

2 (4.9%)

< 0.001

Diabetes mellitus (%)

21 (35%)

2 (4.9%)

< 0.001